- Aurora Cannabis (TSX:ACB) issued a firm denial of recent misinformation circulating online regarding alleged acquisitions and strategic partnerships
- The company became aware of an article posted on a news website falsely claiming that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics
- A second article incorrectly reported that Aurora had signed a partnership with MediPharm (TSX:LABS) distribute medical cannabis in Germany and other European Union markets
- Aurora Cannabis stock (TSX:ACB) last traded at C$6.40
Top Canadian global medical cannabis company Aurora Cannabis (TSX:ACB) has issued a firm denial of recent misinformation circulating online regarding alleged acquisitions and strategic partnerships.
The company became aware of an article posted on a news website falsely claiming that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics. Aurora categorically stated that it has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics regarding a business combination, and has not released or filed any information suggesting such a transaction.
Further compounding the issue, a second article published on June 18, 2025, by Investing.com incorrectly reported that Aurora had signed a partnership with MediPharm (TSX:LABS) to distribute medical cannabis in Germany and other European Union markets (oof, that’s awkward). Aurora has also denied this claim, stating unequivocally that no such agreement or discussions have taken place.
Both articles, which Investing.com claims were generated “with the support of AI” and reviewed by an editor, have prompted Aurora to launch an internal investigation into the origin and dissemination of the misinformation.
Aurora emphasized that it is not in possession of any material non-public information and reaffirmed its commitment to transparency. The company assured the market that any material corporate developments will be communicated directly and appropriately.
The company urged investors to rely solely on official announcements and regulatory filings for accurate and up-to-date information.
Aurora is a global cannabis company serving both the medical and consumer markets across Canada, Europe, Australia and South America. Its brand portfolio includes Drift, San Rafael ’71, Daily Special, Tasty’s, Being, Greybeard, MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co., Pedanios, IndiMed and CraftPlant.
Aurora Cannabis stock (TSX:ACB) last traded at C$6.40 and has risen 4.75 per cent since the year began, but has fallen 15.12 per cent since this time last year.
Join the discussion: Find out what everybody’s saying about this cannabis stock’s expansion in Germany on the Aurora Cannabis Inc. Bullboard and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
